查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600410

老齡化黃斑部病變市場：按類型、治療方法、交付方法、醫療環境、分銷管道 - 2025-2030 年全球預測

Age-related Macular Degeneration Market by Type, Treatment Modality, Delivery Method, Healthcare Setting, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，老齡化黃斑部病變市場價值為104.5億美元，預計到2024年將達到111億美元，複合年成長率為6.67%，到2030年將達到164.3億美元。

老齡化黃斑部病變（AMD）是一個主要的公共衛生問題，也是全世界老年人視力喪失的主要原因。 AMD 市場包括藥物治療，例如抗血管內皮生長因子（抗 VEGF）治療，以及新興的基因和幹細胞治療。隨著世界人口老化和盛行率的增加，AMD 治療方法的進步更加迫切，從而推動了對更有效、更容易獲得的治療方法的需求。最終用途廣泛，包括醫院、眼科診所和研究機構。影響成長的關鍵因素包括醫療保健支出的增加、生物醫學技術的進步以及對 AMD 早期檢測和管理的認知的提高。特別是，新興經濟體中老年人數量的增加代表著一個重大的商機。公司可以透過投資研發來利用這些機會，以創新更有效和更安全的治療方法。建議與醫療保健提供者和患者倡導組織建立合作夥伴關係，以加強市場推廣。

主要市場統計
基準年[2023] 104.5億美元
預測年份 [2024] 111億美元
預測年份 [2030] 164.3億美元
複合年成長率（%） 6.67%

目前的 AMD 治療方法具有較高的治療成本、監管挑戰和潛在的副作用，限制了市場的擴張。此外，AMD發病機制的複雜性使得很難開發出一刀切的解決方案，凸顯了個人化醫療的必要性。創新可以集中在基因研究上，以發現新的生物標記物，用於早期診斷和更個人化的治療方法。此外，對提高治療依從性和患者預後的藥物傳遞系統的投資似乎也很有希望。市場競爭激烈，涉及大型製藥公司、生物技術公司和學術研究機構，使其成為一個動態的局面，需要戰略靈活性。作為一種補充方法，公司應該使其產品組合多樣化，包括替代療法，例如已知支持黃斑部健康的營養食品。與診斷支援和遠端醫療領域的人工智慧技術進步保持同步也有可能開拓新市場。

市場動態：揭示快速發展的老齡化黃斑部病變市場的關鍵市場洞察

供需的動態交互作用正在改變老齡化黃斑部病變市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 世界各地老年人口不斷增加
    • 雷射療法和血管生成抑制劑的使用迅速增加
    • 增加診斷設施和技術以有效偵測AMD
  • 市場限制因素
    • AMD相關藥物召回的潛在風險
  • 市場機會
    • AMD重要的政府政策和資金支持
    • 透過細胞療法和組織工程採用新的先進療法
  • 市場問題
    • 嚴格的法規環境和新治療方法的複雜核准

波特五力：駕馭老齡化黃斑部病變市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對老齡化黃斑部病變市場的影響

外部宏觀環境因素在塑造老齡化黃斑部病變市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解老齡化黃斑部病變市場的競爭格局

對老齡化黃斑部病變市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：老齡化黃斑部病變市場的供應商績效評估

FPNV定位矩陣是評估老齡化黃斑部病變市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製老齡化黃斑部病變市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對老齡化黃斑部病變市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地老年人口數量不斷增加
      • 雷射療法和抗血管新生藥物的使用迅速增加
      • 增加診斷設施和技術以有效檢測 AMD
    • 抑制因素
      • AMD相關藥物召回的潛在風險
    • 機會
      • AMD 的重要政府政策與資金
      • 採用細胞療法和組織工程的新先進治療方法
    • 任務
      • 嚴格的法規環境和新治療方法的複雜核准
  • 市場區隔分析
    • 類型：個人化治療針對乾性 AMD 逐漸和快速視力喪失
    • 治療方法：老齡化黃斑部病變的綜合管理和創新藥物治療
    • 給藥方式：針對老齡化黃斑部病變的創新注射方法
    • 醫療機構：透過 ASC、醫院和診所提供先進且經濟有效的治療方法，為 AMD 管理提供全面護理
    • 分銷管道：分銷 AMD 藥物的線上藥局激增，以確保全面的患者照護
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境
  • 客戶客製化
    • 各國接受治療的患者人數及平均治療費用

第6章老齡化黃斑部病變市場：依類型

  • 介紹
  • 濕性老齡化黃斑部病變
  • 乾老齡化黃斑部病變

老齡化黃斑部病變市場：治療方法

  • 介紹
  • 藥品
    • 發炎藥
    • 抗VEGF劑
    • 抗氧化劑和補充品
    • 基因治療
  • 手術介入
    • 雷射治療
    • 黃斑移位手術
    • 動態療法
    • 玻璃體切除手術

老齡化黃斑部病變市場：按交付方式

  • 介紹
  • 注射
  • 玻璃體內植入
  • 口服

老齡化黃斑部病變市場：依醫療環境分類

  • 介紹
  • 門診手術中心
  • 醫院
  • 眼科診所

老齡化黃斑部病變市場：按分銷管道

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章美洲老齡化黃斑部病變市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太老齡化黃斑部病變市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲老齡化黃斑部病變市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 基因泰克重新推出“Susvimo”，一種改善視力的濕性AMD治療方法
    • Stealth BioTherapeutics 開始 Elamipretide 預防皮膚乾燥並改善患者治療效果的 3 期試驗
    • LambdaVision 獲得資金以推進創新視網膜假體的臨床前測試
    • Science Corporation 收購 Pixium Vision 的 PRIMA 視網膜植入，幫助 AMD 患者恢復視力
    • 香港醫科大學研究人員開發創新光激活奈米藥物以實現更安全、更有效的治療
    • EyeBio 獲得 1.3 億美元 A 輪資金籌措，推進針對老齡化黃斑部病變的 Restoret 療法
    • 安斯泰來製藥宣布有望有效且安全地治療老齡化黃斑部病變
    • FDA核准針對 Aviceda Therapeutics 的 AVD-104 治療老齡化黃斑部病變的臨床試驗
    • 視網膜變性基金的主要投資促進生物技術、推進老齡化黃斑部病變治療並改善生活品質
  • 戰略分析和建議
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Bayer AG
    • Astellas Pharma Inc.

公司名單

  • AbbVie Inc.
  • Adverum BIoTechnologies, Inc.
  • Alkeus Pharmaceuticals, Inc.
  • Allegro Ophthalmics, LLC
  • Amgen Inc.
  • Annexon, Inc.
  • Apellis Pharmaceuticals, Inc.
  • AsclepiX Therapeutics
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biocon Ltd
  • Biogen Inc.
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Formycon AG
  • Grifols, SA
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Kodiak Sciences Inc.
  • Lineage Cell Therapeutics, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Nicox SA
  • Novartis AG
  • PanOptica, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz Group AG
  • Sun Pharmaceutical Industries, Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-F927BA46233D

The Age-related Macular Degeneration Market was valued at USD 10.45 billion in 2023, expected to reach USD 11.10 billion in 2024, and is projected to grow at a CAGR of 6.67%, to USD 16.43 billion by 2030.

Age-related Macular Degeneration (AMD) represents a significant public health concern, being a leading cause of vision loss among the elderly population globally. The market scope encompasses pharmacological therapies, such as anti-vascular endothelial growth factor (anti-VEGF) treatments, along with emerging gene therapies and stem cell approaches. The necessity for advancing AMD therapeutics is underscored by an aging global population and increasing disease prevalence, driving demand for more effective and accessible treatments. Applications extend primarily to the ophthalmology sector, targeting both wet and dry forms of AMD, with end-use spanning hospitals, specialized eye clinics, and research institutions. Key factors influencing growth include rising healthcare expenditure, advancements in biomedical technology, and increasing awareness of early AMD detection and management. Notably, the growing geriatric population in developing economies presents substantial opportunity. Companies can leverage these opportunities by investing in R&D to innovate treatments with better efficacy and safety profiles. Collaborative partnerships with healthcare providers and patient advocacy groups are recommended to enhance market outreach.

KEY MARKET STATISTICS
Base Year [2023] USD 10.45 billion
Estimated Year [2024] USD 11.10 billion
Forecast Year [2030] USD 16.43 billion
CAGR (%) 6.67%

Nonetheless, market expansion faces limitations due to high treatment costs, regulatory challenges, and potential side effects associated with current AMD therapies. Moreover, the complexity of AMD's etiology complicates the development of one-size-fits-all solutions, emphasizing the need for personalized medicine. Innovation could focus on genetic research to uncover new biomarkers for earlier diagnosis or more tailored therapeutic regimens. Additionally, investment in drug delivery systems that enhance treatment adherence and patient outcomes could be promising. The market is competitive and involves major pharmaceutical companies, biotech firms, and academic research institutions, creating a dynamic landscape that requires strategic agility. Companies should diversify their portfolio to include alternative therapies like nutraceuticals known to support macular health as complementary approaches. Keeping pace with technological advancements in AI for diagnostic support and telemedicine also holds potential for new market endeavors.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Age-related Macular Degeneration Market

The Age-related Macular Degeneration Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing number of geriatric population across the world
    • Surging use of laser therapy and anti-angiogenesis drugs
    • Increasing diagnostics facilities and technology for effective detection of AMD
  • Market Restraints
    • Potential risk of drug recalls associated with AMD
  • Market Opportunities
    • Significant government policies & funding for AMD
    • Introduction of novel and advanced treatments based on cell therapy and tissue engineering
  • Market Challenges
    • Stringent regulatory environment and complex approval of new treatments

Porter's Five Forces: A Strategic Tool for Navigating the Age-related Macular Degeneration Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Age-related Macular Degeneration Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Age-related Macular Degeneration Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Age-related Macular Degeneration Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Age-related Macular Degeneration Market

A detailed market share analysis in the Age-related Macular Degeneration Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Age-related Macular Degeneration Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Age-related Macular Degeneration Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Age-related Macular Degeneration Market

A strategic analysis of the Age-related Macular Degeneration Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Age-related Macular Degeneration Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adverum Biotechnologies, Inc., Alkeus Pharmaceuticals, Inc., Allegro Ophthalmics, LLC, Amgen Inc., Annexon, Inc., Apellis Pharmaceuticals, Inc., AsclepiX Therapeutics, Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Biocon Ltd, Biogen Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Formycon AG, Grifols, S.A., Ionis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Kodiak Sciences Inc., Lineage Cell Therapeutics, Inc., Lupin Limited, Merck & Co., Inc., Nicox S.A., Novartis AG, PanOptica, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sandoz Group AG, Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Age-related Macular Degeneration Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Dry Age-Related Macular Degeneration and Wet Age-Related Macular Degeneration.
  • Based on Treatment Modality, market is studied across Pharmaceuticals and Surgical Interventions. The Pharmaceuticals is further studied across Anti-inflammatory Drugs, Anti-VEGF Agents, Antioxidants & Supplements, and Gene Therapy Drugs. The Surgical Interventions is further studied across Laser Therapy, Macular Translocation Surgery, Photodynamic Therapy, and Vitrectomy.
  • Based on Delivery Method, market is studied across Injectable, Intravitreal implants, and Oral.
  • Based on Healthcare Setting, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmology Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing number of geriatric population across the world
      • 5.1.1.2. Surging use of laser therapy and anti-angiogenesis drugs
      • 5.1.1.3. Increasing diagnostics facilities and technology for effective detection of AMD
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of drug recalls associated with AMD
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant government policies & funding for AMD
      • 5.1.3.2. Introduction of novel and advanced treatments based on cell therapy and tissue engineering
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory environment and complex approval of new treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Targeting gradual vision loss in dry AMD and rapid impairment with tailored treatments
    • 5.2.2. Treatment: Comprehensive management and innovative pharmaceutical treatments in age-related macular degeneration
    • 5.2.3. Delivery Method: Innovative injectable methods for age-related macular degeneration
    • 5.2.4. Healthcare Setting: Comprehensive care in AMD management through ASCs, hospitals, and clinics with advanced and cost-effective treatments
    • 5.2.5. Distribution Channel: Proliferation of online pharmacies for distributing AMD drugs to ensure comprehensive patient care
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization
    • 5.5.1. Number of Patients Undergoing Treatments and Average Cost of Treatment By Country

6. Age-related Macular Degeneration Market, by Type

  • 6.1. Introduction
  • 6.2. Dry Age-Related Macular Degeneration
  • 6.3. Wet Age-Related Macular Degeneration

7. Age-related Macular Degeneration Market, by Treatment Modality

  • 7.1. Introduction
  • 7.2. Pharmaceuticals
    • 7.2.1. Anti-inflammatory Drugs
    • 7.2.2. Anti-VEGF Agents
    • 7.2.3. Antioxidants & Supplements
    • 7.2.4. Gene Therapy Drugs
  • 7.3. Surgical Interventions
    • 7.3.1. Laser Therapy
    • 7.3.2. Macular Translocation Surgery
    • 7.3.3. Photodynamic Therapy
    • 7.3.4. Vitrectomy

8. Age-related Macular Degeneration Market, by Delivery Method

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Intravitreal implants
  • 8.4. Oral

9. Age-related Macular Degeneration Market, by Healthcare Setting

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals
  • 9.4. Ophthalmology Clinics

10. Age-related Macular Degeneration Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Age-related Macular Degeneration Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Age-related Macular Degeneration Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Age-related Macular Degeneration Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Genentech relaunches Susvimo for wet AMD with improved vision
    • 14.3.2. Stealth BioTherapeutics launches phase 3 trial for elamipretide to combat dry age-related macular degeneration and improve patient outcomes
    • 14.3.3. LambdaVision secures funding to advance preclinical trials of innovative artificial retina
    • 14.3.4. Science Corporation acquires Pixium Vision's PRIMA retinal implant to enhance vision restoration for AMD patients
    • 14.3.5. Researchers at HKUMed develop groundbreaking photoactivatable nanomedicine for safer and more effective age-related macular degeneration treatment
    • 14.3.6. EyeBio secures USD 130 million Series A funding to advance Restoret therapy for age-related macular degeneration treatment
    • 14.3.7. Astellas Pharma unveils treatment for age-related macular degeneration with promising efficacy and safety results
    • 14.3.8. FDA provides clearance of clinical trials for Aviceda Therapeutics' AVD-104 targeting age-related macular degeneration
    • 14.3.9. Retinal Degeneration Fund's major investment boosts biotech to advance age-related macular degeneration treatments and improve quality of life
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. F. Hoffmann-La Roche Ltd.
    • 14.4.2. Novartis AG
    • 14.4.3. Bayer AG
    • 14.4.4. Astellas Pharma Inc.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adverum Biotechnologies, Inc.
  • 3. Alkeus Pharmaceuticals, Inc.
  • 4. Allegro Ophthalmics, LLC
  • 5. Amgen Inc.
  • 6. Annexon, Inc.
  • 7. Apellis Pharmaceuticals, Inc.
  • 8. AsclepiX Therapeutics
  • 9. Astellas Pharma Inc.
  • 10. Bausch Health Companies Inc.
  • 11. Bayer AG
  • 12. Biocon Ltd
  • 13. Biogen Inc.
  • 14. Clearside Biomedical, Inc.
  • 15. EyePoint Pharmaceuticals, Inc.
  • 16. F. Hoffmann-La Roche Ltd.
  • 17. Formycon AG
  • 18. Grifols, S.A.
  • 19. Ionis Pharmaceuticals, Inc.
  • 20. Johnson & Johnson Services, Inc.
  • 21. Kodiak Sciences Inc.
  • 22. Lineage Cell Therapeutics, Inc.
  • 23. Lupin Limited
  • 24. Merck & Co., Inc.
  • 25. Nicox S.A.
  • 26. Novartis AG
  • 27. PanOptica, Inc.
  • 28. Pfizer Inc.
  • 29. Regeneron Pharmaceuticals, Inc.
  • 30. Sandoz Group AG
  • 31. Sun Pharmaceutical Industries, Ltd.
  • 32. Teva Pharmaceutical Industries Ltd.
  • 33. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. AGE-RELATED MACULAR DEGENERATION MARKET RESEARCH PROCESS
  • FIGURE 2. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AGE-RELATED MACULAR DEGENERATION MARKET DYNAMICS
  • TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTIOXIDANTS & SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY MACULAR TRANSLOCATION SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VITRECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN AGE-RELATED MACULAR DEGENERATION